In order to provide a milestone in the regulation of Nrf2, it is suggested to utilize RNAi and CRISPR technologies to specifically target Nrf2 mutants in HCC therapy lacking impact on normal hepatocytes. Here, NFE2L2 is linked to hepatocellular carcinoma.